The second of the AstraZeneca Takeover stories today is that they are apparently considering a bid for Shire Plc.
Shire is a biopharmaceutical company which specialises in treatments for attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) problems.
Shire have been performing well in the current climate. In their annual review they say:
“Shire visualized a tough future several years ago; it planned for it and continues to execute effectively. The results achieved this year once again demonstrate the wisdom of Shire’s business model.”
Shire closed today at 1,921.86p, down 14p.